Zhimin Shao

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Locally Advanced

Tyrosine Kinase

Metastatic Breast Cancer

Top Venues

British journal of cancer

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Zhimin Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song, Shui Wang, Ting Luo, Wenhe Zhao, Haibo Wang, Yueyin Pan, Jianyun Nie, Xiaohua Zeng, Yanqing Bai, Wendy Chiang, Valeria Guarnaccia, Yu Bi, Binghe Xu
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study. Cancer medicine 13 (15) (2024)
Zhimin Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song, Shui Wang, Ting Luo, Wenhe Zhao, Haibo Wang, Yueyin Pan, Jianyun Nie, Xiaohua Zeng, Yanqing Bai, Wendy Chiang, Valeria Guarnaccia, Yu Bi, Binghe Xu
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study. Cancer medicine 13 (15) (2024)
Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin Shao
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer 131 (4) (2024)
Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin Shao
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer (2024)
Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin Shao
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer 131 (4) (2024)
Zhimin Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song, Shui Wang, Ting Luo, Wenhe Zhao, Haibo Wang, Yueyin Pan, Jianyun Nie, Xiaohua Zeng, Yanqing Bai, Wendy Chiang, Valeria Guarnaccia, Yu Bi, Binghe Xu
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study. Cancer medicine 13 (15) (2024)
Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin Shao
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer 131 (4) (2024)